ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2025
Farnesoid X Receptor Agonist Tropifexor Improves Intestinal Defense Response and Epithelial Barrier Function in Neonatal Piglets Receiving Parenteral Nutrition.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Farnesoid X Receptor Agonist Tropifexor Improves Intestinal Defense Response and Epithelial Barrier Function in Neonatal Piglets Receiving Parenteral Nutrition.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Long-term parenteral nutrition (PN) can lead to liver and intestinal injury in neonates, but effective prevention strategies are limited. Our previous research demonstrated that activation of farnesoid X receptor (FXR) signaling with tropifexor (TXR) could mitigate PN-induced liver damage in neonatal piglets, but its effect on intestinal injury remains to be addressed. In this study, two-day-old Bama minipigs were randomly allocated into three groups (n = 6/group): EN (receiving enteral nutrition, serving as a control), PN, and PT (PN + TXR treatment). Consequently, TXR treatment significantly mitigated PN-induced intestinal injury, including villus atrophy, hyper-permeability, and impaired defense responses. Transcriptomic profiling identified 1188 differentially expressed genes (DEGs) in the PN group compared to EN, among which 108 genes could be substantially attenuated by TXR. Notably, bioinformatics analysis suggested that these DEGs could be classified into "positive regulation of defense response" and "cell-cell adhesion". Moreover, the top 25 hub genes were identified, including EPCAM, CD28, and IFNG. Furthermore, we demonstrated that EPCAM decreased significantly upon PN administration, which could be substantially attenuated by TXR. Finally, in order to further validate the role of TXR in modulating intestinal barrier function, patient-derived organoids (PDOs) were used as a mini-gut model in vitro. Consequently, pharmacological activation of FXR by TXR substantially induced EPCAM expression and enhanced epithelial barrier integrity, particularly in the PDOs derived from pediatric patients receiving PN, while no significant changes were found in those derived from patients receiving oral feeding. In conclusion, this study suggested that TXR treatment could alleviate PN-induced impairment of defense responses and epithelial barrier dysfunction, potentially offering a preventive strategy for neonates receiving long-term PN therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.